CN1244113A - 持效生发剂 - Google Patents
持效生发剂 Download PDFInfo
- Publication number
- CN1244113A CN1244113A CN98802021A CN98802021A CN1244113A CN 1244113 A CN1244113 A CN 1244113A CN 98802021 A CN98802021 A CN 98802021A CN 98802021 A CN98802021 A CN 98802021A CN 1244113 A CN1244113 A CN 1244113A
- Authority
- CN
- China
- Prior art keywords
- preparation
- slow release
- germinal
- minoxidil
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 21
- 230000001256 tonic effect Effects 0.000 title abstract description 4
- 230000002085 persistent effect Effects 0.000 title abstract description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960003632 minoxidil Drugs 0.000 claims abstract description 32
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical group CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 7
- 229940074052 glyceryl isostearate Drugs 0.000 claims description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 4
- XULHFMYCBKQGEE-MRXNPFEDSA-N 2-Hexyl-1-decanol Natural products CCCCCCCC[C@H](CO)CCCCCC XULHFMYCBKQGEE-MRXNPFEDSA-N 0.000 claims description 4
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims 4
- 231100000360 alopecia Toxicity 0.000 claims 4
- 150000005846 sugar alcohols Polymers 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 abstract 1
- -1 fatty acid ester Chemical class 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003779 hair growth Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000002299 Symphytum officinale Species 0.000 description 2
- 235000005865 Symphytum officinale Nutrition 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- QTPGEBNYYFYLFS-UHFFFAOYSA-N butane-1,3-diol;propane-1,2-diol Chemical compound CC(O)CO.CC(O)CCO QTPGEBNYYFYLFS-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000003660 hair regeneration Effects 0.000 description 2
- NCKPXZLHJPKYKE-UHFFFAOYSA-N hexadecan-1-ol 16-methylheptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CC(C)CCCCCCCCCCCCCCCO NCKPXZLHJPKYKE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
一种持效生发制剂,其中含有米诺地尔和二丙二醇,该制剂能保持被吸收的米诺地尔在真皮内留存,并能增高头发生长部位毛球周围米诺地尔的浓度,从而产生充分的生发作用。
Description
所属领域
本发明涉及缓释生发制剂，其中活性成分为米诺地尔。
背景技术
米诺地尔的化学名为6-(1-哌啶基)-2，4-嘧啶二胺-3-氧化物，在美国专利4139619中公开了其适用作生发剂。
过去，含米诺地尔的生发制剂需要每日应用数次，这种应用非常麻烦，并且用户常会忘记，结果有些情况下发现生发效果不足。
发明描述
本发明人根据以下构想进行了各种研究，发明人认为通过保持米诺地尔的在真皮内经皮吸收，即在较长时间内不断增高头发生长部位毛球周围米诺地尔的浓度，能在将米诺地尔用作生发剂时提供一种具有充分生发作用的生发制剂，每日仅需使用1次。
结果，通过将含有米诺地尔的生发制剂与二丙二醇相结合发现二丙二醇能在较长时间内将米诺地尔保持在真皮中，从而完成了本发明。
因此本发明涉及一种含有米诺地尔和二丙二醇的缓释生发制剂。
本发明中米诺地尔的量为0.1-10％(重量)，为其在生发制剂中作为活性成分的常用量。
本发明中二丙二醇的用量优选占制剂总重量的5-40％(重量)。当二丙二醇的用量低于5％(重量)时，米诺地尔在真皮的保留效果不足，当二丙二醇的用量高于40％(重量)时，所得制剂的使用感差。
此外，优选在用纯水将本发明制剂稀释20倍时，其pH调节至4-9，特别是5-8。当制剂的pH超出上述范围时，米诺地尔在真皮中的保留效果会降低，并会刺激皮肤。
本发明的生发制剂中，通过将制剂进一步与1，3-丁二醇或丙二醇结合，能缩短米诺地尔在真皮中达到最大浓度所需的时间(Tmax)。此外，通过将制剂与极性溶剂结合能进一步延长米诺地尔在真皮中的保留时间，极性溶剂选自：2-己基-1-癸醇、异十八醇、二癸酸甘油酯、二辛酸甘油酯、单异硬脂酸甘油酯和丙二醇单异硬脂酸酯。由此将这些成分联合使用能控制生发制剂的剂量和使用次数。
出于对缩短Tmax和对米诺地尔在真皮中保留效果的考虑，当本发明中含有1，3-丁二醇或丙二醇时，其用量优选为0.1-10重量份/1份二丙二醇，优选为0.1-5重量份/1份二丙二醇，此外，出于对延长米诺地尔在真皮中的保留时间和延长米诺地尔在真皮中最大浓度时间的考虑，当制剂与极性溶剂共用时，优选极性溶剂的用量为0.005-5重量份/1份二丙二醇，优选为0.01-2重量份/1份二丙二醇，其中极性溶剂选自：2-己基-1-癸醇、异十八醇、二癸酸甘油酯、二辛酸甘油酯、单异硬脂酸甘油酯和丙二醇单异硬脂酸酯。
本发明制剂中还可含有常用于生发制剂中组分，例如填料、血管扩张剂(卡普氯铵、烟酸苄酯、獐牙菜提取物、人参提取物、乙酸维生素E、辣椒酊等)，抗组胺药(盐酸苯海拉明、盐酸异西喷地等)，抗炎药(甘草次酸、愈创蓝油烃)，角质层分离剂(脲、水杨酸等)，抗微生物剂(葡糖酸洗必太、异丙基甲基苯酚、季铵盐、日柏酚、吡罗克酮醇胺(olamine)等)，保湿剂(透明质酸钠、硫酸软骨素等)，动植物提取物(东北红豆杉、牡丹、甘草、小连翘、乌头根、枇杷、茵陈蒿、西门肺草(Symphytum officinale)、当归(Angelica keiskei)、番红花、栀子、Posmarinus officinalis、药鼠尾草、风毛菊根、马兜铃、蛇麻孢子球(Lupuli strobilus)、胎盘等)，维生素(乙酸视黄醇、盐酸吡哆辛、抗坏血酸、硝酸硫胺、维生素B12、生物素等)，水，低级醇(甲醇、乙醇、变性乙醇、异丙醇等)，抗氧剂(二丁基羟甲苯、焦亚硫酸钠、生育酚、乙二胺四乙酸二钠、抗坏血酸、没食子酸异丙酯等)，助溶剂(己二酸二异丙酯、肉豆蔻酸异丙酯、聚乙二醇、中等链长的脂肪酸三甘酯、脂肪酸酯、植物油、动物油、多元醇脂肪酸酯、烷基甘油醚、烃、乳酸、氢氧化钠等)，代谢活化剂(泛醇等)，表面活性剂(脱水山梨醇脂肪酸酯、甘油脂肪酸酯、聚甘油脂肪酸酯、丙二醇脂肪酸酯、聚氧乙烯脱水山梨醇脂肪酸酯、聚氧乙烯山梨醇脂肪酸酯、聚氧乙烯甘油脂肪酸酯、聚氧乙烯甘醇脂肪酸酯、聚乙二醇脂肪酸酯、聚乙二醇烷基醚、聚氧乙烯聚氧丙烯烷基醚、聚氧乙烯烷基苯基醚、聚氧乙烯氢化蓖麻油、聚氧乙烯蓖麻油、聚氧乙烯蜂蜡衍生物、聚氧乙烯羊毛脂衍生物、聚氧乙烯烷基酰胺、聚氧乙烯烷基胺、卵磷脂衍生物、高分子乳化剂等)，乳化稳定剂(高级醇等)，胶凝剂(水溶性高分子化合物等)，增稠剂、香精、清凉剂(薄荷醇、薄荷油、樟脑等)或染料。当其中含有水或低级醇时，水的含量优选约占制剂总量的0.5-30％(重量)，当所含的低级醇是乙醇或异丙醇时，其用量优选占制剂总量的50-90％(重量)。
可采用常规方法将本发明的生发制剂制成外用制剂的剂型，如膏霜、软膏、气溶胶、乳液或生发水。此外，本发明的缓释生发制剂还可以适宜的用量每日或每隔几日经皮施用。
本发明的最佳实施方案
将通过以下实施例和实验来进一步详细说明本发明。
表1所示的配方中，将米诺地尔和二丙二醇与其它组分混合，与无水乙醇和纯水形成总体积100毫升，经搅拌溶解，从而得到实施例1-13和对照实施例1和2的乳液型外用生发制剂。
表1
单位：克
| 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | 实施例7 | 实施例8 | ||||||
| 米诺地尔 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
| 二丙二醇 | 20 | 15 | 15 | 15 | 20 | 20 | 20 | 20 | |||||
| 1，3-丁二醇丙二醇 | 5 | 5 | 2.52.5 | ||||||||||
| 单异硬酯酸甘油酯单异硬脂酸丙二醇酯二癸酸甘油酯 | 2 | 2 | 2 | ||||||||||
| 异硬脂醇十六烷醇 | 2 | ||||||||||||
| 无水乙醇 | 60ml | ||||||||||||
| 纯水 | 总量100ml | ||||||||||||
| 稀释20倍时的pH | 7.4 | 7.2 | 7.2 | 7.1 | 7.0 | 7.0 | 7.0 | 7.2 | |||||
表1(续)单位：克
实验1.米诺地尔在血液中的浓度以及米诺地尔在真皮中的含量
| 实施例9 | 实施例10 | 实施例11 | 实施例12 | 实施例13 | 对照实施例1 | 对照实施例2 | |
| 米诺地尔 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 二丙二醇 | 20 | 30 | 40 | 3 | 5 | ||
| 1，3-丁二醇丙二醇 | |||||||
| 单异硬脂酸甘油酯单异硬脂酸丙二醇酯二癸酸甘油酯 | 20 | ||||||
| 异硬脂醇十六烷醇 | 2 | ||||||
| 无水乙醇 | 60ml | 总量100ml | 60ml | ||||
| 纯水 | 总量100ml | - | 总量10ml | ||||
| 稀释20倍时的pH | 7.1 | 7.2 | 7.3 | 7.2 | 7.1 | 7.5 | 7.4 |
剃去7周大的雄性Wister鼠腹部的毛，乙醚麻醉后仰卧摆放，分别在腹部规定区域(2×4cm)涂敷40μl表1中各乳液。经规定时间(1、2、4、6、8、12和24小时)，从胸静脉收集血液，采用液体闪烁计数器测定血液中米诺地尔的浓度，血液中浓度的变化见表2。此外，为进一步测定真皮中米诺地尔的浓度，采用断头术使鼠致死，用乙醇洗涤涂有乳液的表皮，切除皮肤，并用透明胶带紧紧贴住整片表皮，包在塑料保鲜膜中，浸入60℃热水浴中60秒。冷却后剥去胶带，以便除去皮肤上剩余的药物和表皮层，测定剩余真皮的重量和真皮中米诺地尔的含量，其含量以每1克真皮所含的米诺地尔计。真皮中该浓度的变化见表3。
表中“h”表示小时，“Ex.”表示实施例，“Cmp”表示对照实施例。
表2 单位：ng/ml
| 0h | 1h | 2h | 4h | 6h | 8h | 12h | 24h | |
| Ex.1 | 0.00 | 1.00 | 2.00 | 3.00 | 2.67 | 2.00 | 1.00 | 0.00 |
| Ex.2 | 0.00 | 1.33 | 2.33 | 3.33 | 3.00 | 2.33 | 1.00 | 0.00 |
| Ex.3 | 0.00 | 1.67 | 2.67 | 3.33 | 3.00 | 2.00 | 1.00 | 0.00 |
| Ex.4 | 0.00 | 1.33 | 2.33 | 3.00 | 2.33 | 1.67 | 0.67 | 0.00 |
| Ex.5 | 0.00 | 0.33 | 1.33 | 2.67 | 1.67 | 1.33 | 0.67 | 0.00 |
| Ex.6 | 0.00 | 1.00 | 1.67 | 2.33 | 1.33 | 0.33 | 0.00 | 0.00 |
| Ex.7 | 0.00 | 1.00 | 1.67 | 3.33 | 2.33 | 1.00 | 0.33 | 0.00 |
| Ex.8 | 0.00 | 1.67 | 2.33 | 3.00 | 2.67 | 1.33 | 1.00 | 0.00 |
| Ex.9 | 0.00 | 2.33 | 3.00 | 2.67 | 2.00 | 1.33 | 0.67 | 0.00 |
| Ex.10 | 0.00 | 1.10 | 1.95 | 2.50 | 3.30 | 2.71 | 2.00 | 0.00 |
| Ex.11 | 0.00 | 1.20 | 1.60 | 2.40 | 3.00 | 3.30 | 2.40 | 0.00 |
| Ex.12 | 0.00 | 3.50 | 6.31 | 3.24 | 1.82 | 0.78 | 0.55 | 0.00 |
| Ex.13 | 0.00 | 2.10 | 2.78 | 3.20 | 2.21 | 1.35 | 0.78 | 0.00 |
| Cmp.1 | 0.00 | 8.00 | 2.25 | 0.68 | 0.23 | 0.22 | 0.15 | 0.05 |
| Cmp.2 | 0.00 | 10.00 | 7.00 | 3.00 | 1.50 | 0.60 | 0.25 | 0.00 |
表3 μg/lg皮肤
| 0h | 1h | 2h | 4h | 6h | 8h | 12h | 24h | |
| Ex.1 | 0 | 2 | 4 | 8 | 12 | 15 | 18 | 8 |
| Ex.2 | 0 | 2 | 5 | 7 | 9 | 12 | 8 | 3 |
| Ex.3 | 0 | 5 | 8 | 14 | 9 | 7 | 4 | 1 |
| Ex.4 | 0 | 3 | 5 | 9 | 13 | 8 | 6 | 2 |
| Ex.5 | 0 | 0 | 2 | 3 | 5 | 8 | 9 | 6 |
| Ex.6 | 0 | 0 | 4 | 5 | 8 | 10 | 12 | 8 |
| Ex.7 | 0 | 0 | 3 | 5 | 7 | 9 | 11 | 7 |
| Ex.8 | 0 | 1 | 2 | 4 | 6 | 8 | 10 | 5 |
| Ex.9 | 0 | 2 | 3 | 5 | 7 | 9 | 11 | 6 |
| Ex.10 | 0 | 3 | 4 | 9 | 14 | 17 | 21 | 11 |
| Ex.11 | 0 | 5 | 7 | 10 | 15 | 18 | 27 | 16 |
| Ex.12 | 0 | 3 | 6 | 8 | 4 | 2 | 0 | 0 |
| Ex.13 | 0 | 1 | 3 | 5 | 6 | 8 | 7 | 1 |
| Cmp.1 | 0 | 6 | 2 | 1 | 1 | 0 | 0 | 0 |
| Cmp.2 | 0 | 4 | 9 | 3 | 2 | 1 | 0 | 0 |
表2和3的结果表明：与对照实施例相比，本发明的缓释生发制剂能更有效地降低米诺地尔在血液中扩散，并且相反还能在较长时间内增加真皮中米诺地尔的浓度。实施例2.头发再生试验
每组采用10只7周大的C3H鼠，用发剪剪去各组小鼠背部面积为2×3cm的毛发用于测试。规定不同组的鼠分别每日一次在脱毛的部位涂敷0.2ml表1中的试样。
试验用动物的体毛为黑色，脱毛部位的皮肤为褐色，因此随着毛发生长能令颜色由褐变黑，因此根据以下6级对黑发的程度进行目测：0：未发现毛发再生，1：发现毛发再生，2：毛发末端生出，3：毛发末端长至普通毛发的50％，4：毛发末端长至普通毛发的70％，以及6：毛发末端长至普通毛发的100％。结果见表4。
表4
| 试样 | 目测 | |
| 10天后 | 20天后 | |
| 实施例1实施例2实施例3实施例4实施例5实施例6实施例7实施例8实施例9实施例10实施例11实施例12实施例13对照实施例1对照实施例2 | 322222222331211 | 555555555555534 |
表4表明：与对照实施例相比，本发明的制剂的头发再生程度更高。
工业实用性
本发明能令米诺地尔保留在真皮中，从而提供了一种仅需涂敷数次就有效果的缓释生发制剂。
Claims (11)
1.一种缓释生发制剂，其中含有米诺地尔和二丙二醇。
2.权利要求1的缓释生发制剂，其中该制剂经纯水稀释20倍后的pH为4-9。
3.权利要求1的缓释生发制剂，其中米诺地尔的量占制剂总重量的0.1-10％重量。
4.权利要求1的缓释生发制剂，其中二丙二醇的量占制剂总重量的5-40％重量。
5.权利要求1-4中任一权利要求中的缓释生发制剂，其中还含有至少一种极性溶剂，其选自：2-己基-1-癸醇、异十八醇、二癸酸甘油酯、二辛酸甘油酯、单异硬脂酸甘油酯和丙二醇单异硬脂酸酯。
6.权利要求1-4中任一权利要求中的缓释生发制剂，其中还含有至少一种极性溶剂，其选自：2-己基-1-癸醇、异十八醇、二癸酸甘油酯、二辛酸甘油酯、单异硬脂酸甘油酯和丙二醇单异硬脂酸酯，其用量为0.005-5重量份/1重量份二丙二醇。
7.权利要求1-4中任一权利要求中的缓释生发制剂，其中还含有至少一种多元醇，其选自1，3-丁二醇和丙二醇。
8.权利要求1-4中任一权利要求中的缓释生发制剂，其中还含有至少一种多元醇，其选自1，3-丁二醇和丙二醇，其用量占制剂的0.1-10％重量。
9.权利要求1-4中任一权利要求中的缓释生发制剂，其中还含有至少一种多元醇，其选自1，3-丁二醇和丙二醇，其用量为0.1-10重量份/1重量份二丙二醇。
10.一种治疗秃发、脱发和头发稀疏病症的方法，其中包括施用权利要求1-9中任一权利要求中的缓释生发制剂。
11.权利要求1-9中缓释生发制剂在制备治疗秃发、脱发和头发稀疏病症的药物制剂的用途。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1053197 | 1997-01-23 | ||
| JP10531/1997 | 1997-01-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1244113A true CN1244113A (zh) | 2000-02-09 |
| CN1154463C CN1154463C (zh) | 2004-06-23 |
Family
ID=11752850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988020211A Expired - Fee Related CN1154463C (zh) | 1997-01-23 | 1998-01-22 | 持效生发剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6255313B1 (zh) |
| EP (1) | EP0970683A4 (zh) |
| KR (1) | KR20000070370A (zh) |
| CN (1) | CN1154463C (zh) |
| AU (1) | AU729411B2 (zh) |
| CA (1) | CA2277946A1 (zh) |
| HK (1) | HK1024407A1 (zh) |
| WO (1) | WO1998032417A1 (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314393C (zh) * | 2001-05-31 | 2007-05-09 | 辉瑞产品公司 | 用拟甲状腺化合物治疗掉发的方法 |
| CN100361644C (zh) * | 2000-04-07 | 2008-01-16 | 大正制药株式会社 | 毛发生长组合物 |
| CN100367923C (zh) * | 1999-10-29 | 2008-02-13 | 株式会社资生堂 | 异硬脂醇作为经毛吸收促进成分的应用 |
| CN100577168C (zh) * | 2007-03-21 | 2010-01-06 | 遵义医学院附属医院 | 治疗脱发的乳膏剂及其制备方法 |
| CN103285082A (zh) * | 2013-06-13 | 2013-09-11 | 江苏红豆杉药业有限公司 | 一种用于治疗妇科炎症的药物组合物 |
| CN110755286A (zh) * | 2019-11-18 | 2020-02-07 | 童婧 | 一种有助于生发的发际线填充组合物 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
| AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| JP4610040B2 (ja) | 2000-04-04 | 2011-01-12 | 東レ・ダウコーニング株式会社 | 育毛剤用添加剤及び育毛剤組成物 |
| US20030157046A1 (en) * | 2000-04-07 | 2003-08-21 | Koji Imamura | Minoxidil-containing preparations |
| WO2001078662A1 (fr) * | 2000-04-07 | 2001-10-25 | Taisho Pharmaceutical Co. Ltd. | Compositions de toniques capillaires a action durable |
| JPWO2001076540A1 (ja) * | 2000-04-07 | 2004-01-08 | 大正製薬株式会社 | 育毛組成物 |
| WO2004010958A2 (en) * | 2002-07-31 | 2004-02-05 | Shaklee Corporation | A method for maximizing scalp health and inducing enhanced visual and tactile hair quality |
| US8147815B2 (en) * | 2005-12-16 | 2012-04-03 | Celmatrix Corporation | Topical administration carrier composition and therapeutic formulations comprising same |
| US20080206156A1 (en) * | 2007-02-22 | 2008-08-28 | Cronk Peter J | Continuous spray scalp therapy and dispensing systems for same |
| US8021649B2 (en) | 2007-02-22 | 2011-09-20 | Cronk Peter J | Continuous spray scalp therapy and dispensing systems for same |
| KR101948238B1 (ko) * | 2016-08-19 | 2019-02-14 | (주)케어젠 | 미녹시딜과 펩타이드의 결합체 |
| US9962444B2 (en) | 2016-09-27 | 2018-05-08 | Shane Malek | Pharmacokinetically extended action topical hair growth formulation, and administration method |
| KR20210156157A (ko) | 2020-06-17 | 2021-12-24 | (주)큐젠바이오텍 | 베타글루칸 및 미녹시딜을 유효성분으로 포함하는 탈모 방지 또는 발모 개선용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
| JPH0745387B2 (ja) * | 1987-09-09 | 1995-05-17 | 株式会社資生堂 | 発毛、養毛促進剤 |
| JPH01132510A (ja) | 1987-11-17 | 1989-05-25 | Taisho Pharmaceut Co Ltd | 養毛剤 |
| JP2733980B2 (ja) * | 1988-08-26 | 1998-03-30 | 大正製薬株式会社 | 養毛組成物 |
| DE4215478A1 (de) | 1992-05-11 | 1993-11-18 | Solvay Deutschland | Lactobionsäureamidzusammensetzungen und deren Verwenndung |
| GB9210756D0 (en) * | 1992-05-20 | 1992-07-08 | Unilever Plc | Cosmetic composition |
| GB2274060A (en) * | 1993-01-07 | 1994-07-13 | Merck & Co Inc | Treatment of patterned alopecia with 17ß-acyl-4-aza-5-androst-1-ene-3-ones and minoxidil |
| JPH08277209A (ja) * | 1995-04-07 | 1996-10-22 | Taisho Pharmaceut Co Ltd | 育毛剤 |
-
1998
- 1998-01-22 US US09/341,191 patent/US6255313B1/en not_active Expired - Fee Related
- 1998-01-22 CA CA002277946A patent/CA2277946A1/en not_active Abandoned
- 1998-01-22 CN CNB988020211A patent/CN1154463C/zh not_active Expired - Fee Related
- 1998-01-22 AU AU55756/98A patent/AU729411B2/en not_active Ceased
- 1998-01-22 WO PCT/JP1998/000227 patent/WO1998032417A1/ja not_active Application Discontinuation
- 1998-01-22 KR KR1019997006603A patent/KR20000070370A/ko not_active IP Right Cessation
- 1998-01-22 EP EP98900688A patent/EP0970683A4/en not_active Withdrawn
-
2000
- 2000-06-21 HK HK00103736A patent/HK1024407A1/xx not_active IP Right Cessation
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367923C (zh) * | 1999-10-29 | 2008-02-13 | 株式会社资生堂 | 异硬脂醇作为经毛吸收促进成分的应用 |
| CN100361644C (zh) * | 2000-04-07 | 2008-01-16 | 大正制药株式会社 | 毛发生长组合物 |
| CN1314393C (zh) * | 2001-05-31 | 2007-05-09 | 辉瑞产品公司 | 用拟甲状腺化合物治疗掉发的方法 |
| CN100577168C (zh) * | 2007-03-21 | 2010-01-06 | 遵义医学院附属医院 | 治疗脱发的乳膏剂及其制备方法 |
| CN103285082A (zh) * | 2013-06-13 | 2013-09-11 | 江苏红豆杉药业有限公司 | 一种用于治疗妇科炎症的药物组合物 |
| CN103285082B (zh) * | 2013-06-13 | 2015-02-11 | 江苏红豆杉药业有限公司 | 一种用于治疗妇科炎症的药物组合物 |
| CN110755286A (zh) * | 2019-11-18 | 2020-02-07 | 童婧 | 一种有助于生发的发际线填充组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1154463C (zh) | 2004-06-23 |
| US6255313B1 (en) | 2001-07-03 |
| HK1024407A1 (en) | 2000-10-13 |
| AU5575698A (en) | 1998-08-18 |
| KR20000070370A (ko) | 2000-11-25 |
| WO1998032417A1 (fr) | 1998-07-30 |
| EP0970683A1 (en) | 2000-01-12 |
| EP0970683A4 (en) | 2005-08-24 |
| AU729411B2 (en) | 2001-02-01 |
| CA2277946A1 (en) | 1998-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1154463C (zh) | 持效生发剂 | |
| US8632759B2 (en) | Hair restorer | |
| US4978681A (en) | Hair-growing agent | |
| US5096697A (en) | Method of stimulating hair growth with aliphatic alcohols | |
| EP0944310B1 (en) | Stabilized ascorbyl compositions | |
| RU95122759A (ru) | Слабораздражающий косметический состав для ухода за кожей (варианты), его применение (варианты) и производство | |
| CN1263442C (zh) | 持续性毛发生长组合物 | |
| US6001378A (en) | Combinations of peroxide lipids and organosilicon compounds, cosmetic and dermatological compositions containing same, and uses thereof, in particular for treating alopecia | |
| US20070154432A1 (en) | Compositions and methods for hair growth | |
| US20030031639A1 (en) | Hair growth promoter | |
| CN114848517A (zh) | 一种保湿控油消炎抑菌祛痘组合物和包含该组合物的祛痘化妆品及其制备方法 | |
| JP3220761B2 (ja) | 養毛料 | |
| JP5872752B2 (ja) | 皮脂硬化物溶解能を有する養毛剤 | |
| CN1303302A (zh) | 含有米诺地尔的外用组合物 | |
| JP6821916B2 (ja) | 外用組成物 | |
| JPH07206647A (ja) | 養毛料 | |
| JPH0920613A (ja) | 化粧料 | |
| JPH066525B2 (ja) | 養毛料 | |
| JPH0640858A (ja) | 養毛料 | |
| JPH10218736A (ja) | 育毛剤 | |
| CN115671022A (zh) | 一种抗衰老微胶囊组合物及其制备方法和应用 | |
| JPH07228511A (ja) | 養毛料 | |
| WO2011080743A1 (en) | Alcohol gel for reducing hair growth | |
| JPH07228512A (ja) | 養毛料 | |
| JPH01207224A (ja) | 頭髪用化粧料及び養毛剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040623 Termination date: 20100222 |